#United States #Florida #Biofidelity #Enspyre #Genomic Technology

Biofidelity to Launch Enspyre® Technology at AGBT 2025

Biofidelity, renowned for its innovative genomic solutions, is preparing to unveil its latest technology, Enspyre®, at the upcoming Advances in Genome Biology and Technology (AGBT) General Meeting held in Marco Island, Florida from February 23-26, 2025. This groundbreaking target enrichment technology is set to transform the landscape of next-generation sequencing (NGS).

What is Enspyre®?

Enspyre® stands for Enrichment by selective pyrophosphorolysis and release, a technology designed to enhance the sensitivity of variant calling from sequencing data. According to Biofidelity's Co-founder and CEO, Dr. Barnaby Balmforth, traditional NGS processes can be inefficient, often yielding variant calls from only one in twenty million sequenced bases. This inefficiency leads to a poor signal-to-noise ratio, which limits the capabilities of NGS and the potential applications in the genomic field.

The Magic of Enspyre®

Enspyre® drastically improves this ratio by removing up to 99% of background DNA before sequencing. This capability allows for high-throughput NGS applications on benchtop sequencers, thereby unlocking a myriad of new uses in clinical settings and scientific research. Notably, the technology presents a significant advancement in oncological applications, such as minimum residual disease (MRD) testing.

The advantages of Enspyre® extend beyond enhanced sensitivity. By reducing the sequencing depth requirement by over 95% compared to non-selective assays, it streamlines the data processing time and decreases the storage requirements. These efficiencies combined have the potential to lower sequencing costs while delivering results much faster for patients, thus significantly improving patient care in oncology.

Demonstration at AGBT 2025

At the AGBT conference, Biofidelity will share proof-of-concept data for Enspyre®. The presentation titled "Enspyre: A Novel Enrichment Technology for Selected DNA Variants Using Pyrophosphorolysis" will take place on February 25, 2025, from 4:45 to 6:10 PM EST at poster #434. This presentation will showcase how Enspyre® can redefine the capabilities of NGS.

Collaboration and Future Directions

Biofidelity is keen on integrating Enspyre® into its existing offerings, enhancing its PCR-based Aspyre® technology, which focuses on non-small cell lung cancer biomarkers through expedited, decentralized testing. The aim is to create a comprehensive product pipeline addressing significant unmet clinical needs in oncology.

In a strategic move, Biofidelity is implementing an "Intel Inside" approach to commercialize Enspyre®, actively seeking partnerships and licensing agreements with leading global pharmaceutical firms, contract research organizations (CROs), and developers of precision medicine.

Conclusion

By launching Enspyre® at AGBT 2025, Biofidelity is poised to make a substantial impact on genomic testing and cancer treatment strategies. This novel technology has the potential to enhance the identification and analysis of genetic variants in a more efficient, cost-effective manner, thereby improving outcomes for patients globally. For more information on Enspyre®, visit biofidelity.com/products/enspyre.

About Biofidelity

Biofidelity is an innovative genomic technology company committed to improving the lives of cancer patients by facilitating better targeting of therapies and monitoring treatment responses. Connect with Biofidelity on LinkedIn for the latest updates on their technologies.